PL3097189T3 - Chimeryczne białka podobne do alkalicznej fosfatazy - Google Patents

Chimeryczne białka podobne do alkalicznej fosfatazy

Info

Publication number
PL3097189T3
PL3097189T3 PL15703642T PL15703642T PL3097189T3 PL 3097189 T3 PL3097189 T3 PL 3097189T3 PL 15703642 T PL15703642 T PL 15703642T PL 15703642 T PL15703642 T PL 15703642T PL 3097189 T3 PL3097189 T3 PL 3097189T3
Authority
PL
Poland
Prior art keywords
alkaline phosphatase
chimeric proteins
proteins similar
similar
chimeric
Prior art date
Application number
PL15703642T
Other languages
English (en)
Inventor
Willem Raaben
Luigi Johannes Cornelius Jonk
Andrea Van Elsas
Erik Jan VAN DEN BERG
José Luis MILLÁN
Original Assignee
Am-Pharma B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Am-Pharma B.V. filed Critical Am-Pharma B.V.
Publication of PL3097189T3 publication Critical patent/PL3097189T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/465Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52Genes encoding for enzymes or proenzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y301/00Hydrolases acting on ester bonds (3.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y301/00Hydrolases acting on ester bonds (3.1)
    • C12Y301/03Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03001Alkaline phosphatase (3.1.3.1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
PL15703642T 2014-01-24 2015-01-26 Chimeryczne białka podobne do alkalicznej fosfatazy PL3097189T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP14152526 2014-01-24
EP14188158 2014-10-08
EP15703642.7A EP3097189B1 (en) 2014-01-24 2015-01-26 Chimeric alkaline phosphatase-like proteins
PCT/NL2015/050048 WO2015112017A1 (en) 2014-01-24 2015-01-26 Chimeric alkaline phosphatase-like proteins

Publications (1)

Publication Number Publication Date
PL3097189T3 true PL3097189T3 (pl) 2018-11-30

Family

ID=52464544

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15703642T PL3097189T3 (pl) 2014-01-24 2015-01-26 Chimeryczne białka podobne do alkalicznej fosfatazy

Country Status (22)

Country Link
US (4) US9926544B2 (pl)
EP (2) EP3425048A1 (pl)
JP (3) JP6940949B2 (pl)
KR (1) KR102166110B1 (pl)
CN (2) CN111778228A (pl)
AU (1) AU2015209783B2 (pl)
BR (1) BR112016017041B1 (pl)
CA (1) CA2937328C (pl)
DK (1) DK3097189T3 (pl)
ES (1) ES2684639T3 (pl)
HU (1) HUE039784T2 (pl)
IL (1) IL246898B (pl)
MX (1) MX369041B (pl)
PE (1) PE20161442A1 (pl)
PH (1) PH12016501441B1 (pl)
PL (1) PL3097189T3 (pl)
RU (1) RU2683635C2 (pl)
SA (1) SA516371532B1 (pl)
SG (1) SG11201606060WA (pl)
SI (1) SI3097189T1 (pl)
WO (1) WO2015112017A1 (pl)
ZA (1) ZA201605028B (pl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12016501441B1 (en) 2014-01-24 2023-02-22 Am Pharma Bv Chimeric alkaline phosphatase-like proteins
WO2016007873A1 (en) 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions and methods for treating craniosynostosis
BR112017011900A2 (pt) 2014-12-05 2018-02-27 Alexion Pharma Inc tratamento de ataques com fosfatase alcalina recombinante
CA2973883A1 (en) 2015-01-28 2016-08-04 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
AU2016308624B2 (en) * 2015-08-17 2022-06-23 Alexion Pharmaceuticals, Inc. Manufacturing of alkaline phosphatases
WO2017074466A1 (en) 2015-10-30 2017-05-04 Alexion Pharmaceuticals, Inc. Methods for treating craniosynostosis in a patient
US11065306B2 (en) 2016-03-08 2021-07-20 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
US11186832B2 (en) 2016-04-01 2021-11-30 Alexion Pharmaceuticals, Inc. Treating muscle weakness with alkaline phosphatases
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
EP3345614A1 (en) * 2017-01-05 2018-07-11 Amrif B.V. Composition comprising alkaline phosphatase for use in the treatment of arthritides
CN110719786A (zh) 2017-03-31 2020-01-21 阿雷克森制药公司 用于治疗成人和青少年的低磷酸酯酶症(hpp)的方法
US11338020B2 (en) 2018-01-09 2022-05-24 Synthetic Biologics, Inc. Alkaline phosphatase agents for treatment of neurodevelopmental disorders
PT3762018T (pt) 2018-03-08 2024-05-07 Am Pharma Bv Fosfatase alcalina recombinante para utilização no tratamento de lesão renal aguda associada a septicemia
ES3032290T3 (en) 2018-03-20 2025-07-16 Theriva Biologics Inc Intestinal alkaline phosphatase formulations
EP3773686B1 (en) 2018-03-20 2023-06-07 Theriva Biologics, Inc. Alkaline phosphatase agents for treatment of radiation disorders
US11913039B2 (en) 2018-03-30 2024-02-27 Alexion Pharmaceuticals, Inc. Method for producing recombinant alkaline phosphatase
CN110499284A (zh) * 2018-05-17 2019-11-26 西安组织工程与再生医学研究所 Wnt信号通路激活剂在制备治疗基因ALPL敲除小鼠牙硬组织矿化异常产品中的应用
EP3833377B1 (en) 2018-08-10 2023-11-22 Alexion Pharmaceuticals, Inc. Bone healing at implants using alkaline phosphatase
CN113993541A (zh) 2019-05-06 2022-01-28 合成生物制品有限公司 基于碱性磷酸酶的肿瘤学治疗
MX2022007114A (es) 2019-12-09 2022-07-11 Alexion Pharma Inc Polipeptidos de fosfatasa alcalina y metodos de uso de los mismos.
JP2023510195A (ja) * 2020-01-03 2023-03-13 ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ 歯周の健康を促進するために局所投与されるtnap
CN111110835A (zh) * 2020-01-22 2020-05-08 李鑫荣 一种肠碱性磷酸酶的新应用及其制剂的细胞活性检测方法
EP4210731A1 (en) 2020-09-09 2023-07-19 AM-Pharma B.V. Recombinant alkaline phosphatase for use in treating acute respiratory distress syndrome
BR112023016048A2 (pt) 2021-02-12 2023-11-14 Alexion Pharma Inc Polipeptídeos de fosfatase alcalina e métodos de uso dos mesmos
CN118580341B (zh) * 2024-06-24 2025-03-18 浙江大学 一种寄生线虫spi-i8蛋白及其在防治炎症疾病中的应用

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8328918D0 (en) 1983-10-28 1983-11-30 Unilever Plc Alkaline phosphatase
EP0441252B1 (en) 1990-02-07 1997-09-03 Abbott Laboratories Alkaline phosphatase enzymes having improved specific activity for use in indicator reagents
WO1993018139A1 (en) 1992-03-10 1993-09-16 La Jolla Cancer Research Foundation Recombinant calf intestinal alkaline phosphatase
JPH06284885A (ja) * 1993-04-02 1994-10-11 Tosoh Corp 組換えヒト小腸アルカリフォスファタ−ゼ
AU698101B2 (en) 1993-06-01 1998-10-22 Cortex Pharmaceuticals, Inc. Alkaline and acid phosphatase inhibitors in treatment of neurological disorders
WO1995005455A1 (en) 1993-08-13 1995-02-23 Rijksuniversiteit Te Groningen Pharmaceutical composition comprising phosphatase or a derivative thereof
ATE225666T1 (de) 1993-11-15 2002-10-15 Celtrix Pharma Verwendung von igf-1 und igfbp-3 zur herstellung eines arzneimittels zur behandlung von einer nierenerkrankung
CA2222626A1 (en) 1995-06-06 1996-12-12 Biocoll Laboratories, Inc. Modified osteogenic materials
FR2736065B1 (fr) 1995-06-29 1997-09-19 Commissariat Energie Atomique Phosphatases alcalines bacteriennes modifiees et leurs applications.
JP3488327B2 (ja) 1995-12-21 2004-01-19 よつ葉乳業株式会社 牛乳脂肪球膜含有画分の製造法
US20020114802A1 (en) 1998-02-10 2002-08-22 Tjellstrom Bo Arthur Einar Oral immunoglobulin treatment for inflammatory bowel disease
DE19819962A1 (de) 1998-05-05 1999-11-11 Roche Diagnostics Gmbh Hochaktive alkalische Phosphatase
JP2002533679A (ja) 1998-12-21 2002-10-08 フアーマアウエア・アイピー・ベー・ブイ アルカリホスファターゼのlps−結合部分を使用する敗血症の診断
JP2000350596A (ja) 1999-06-11 2000-12-19 Toyobo Co Ltd 分泌性アルカリフォスファターゼの選択的活性測定方法
ATE327751T1 (de) 2000-01-31 2006-06-15 Pfizer Prod Inc Verwendung von aktivatoren des prostaglandinrezeptores 4 zur behandlung von akuter oder chronischer niereninsuffizienz
KR100799192B1 (ko) 2000-07-19 2008-01-31 미쯔비시 웰 파마 가부시키가이샤 히드록삼산계 설폰산 유도체 및 그의 의약 용도
EP1191097A1 (en) 2000-09-21 2002-03-27 Leids Universitair Medisch Centrum Induction of exon skipping in eukaryotic cells
DE10101793A1 (de) 2001-01-17 2002-08-01 Manfred Nilius Verwendung von SLPI zur Behandlung chronisch-entzündlicher Darmerkrankungen
EP1370642A2 (en) 2001-01-20 2003-12-17 Cardion AG Pluripotent adult stem cells derived from regenerative tissue
JP4238726B2 (ja) 2001-06-01 2009-03-18 味の素株式会社 腸疾患用の薬剤
US7157260B2 (en) 2001-07-26 2007-01-02 Japan Science & Technology Agency Nicotianamine synthase and gene encoding the same
JP4169966B2 (ja) 2001-11-14 2008-10-22 株式会社ヤクルト本社 炎症性腸疾患予防治療剤
CN1425766A (zh) 2001-12-19 2003-06-25 复旦大学 一种多肽——人含碱性磷酸酶活性位点的蛋白-9.24和编码这种多肽的多核苷酸
US20040146907A1 (en) * 2002-11-13 2004-07-29 Genentech, Inc. Methods and compositions for detecting dysplasia
US7048914B2 (en) 2002-12-12 2006-05-23 Zoltan Laboratories Placental alkaline phosphatase to control diabetes
WO2004056987A1 (en) * 2002-12-23 2004-07-08 Rijksuniversiteit Groningen Modulation of the thioredoxin pathway
AU2003225410A1 (en) 2003-03-21 2004-10-11 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
JP4305071B2 (ja) 2003-06-30 2009-07-29 株式会社ニコン 信号補正方法
JP2005065564A (ja) 2003-08-22 2005-03-17 Hiroshi Ueda センサー蛋白質
US7157261B2 (en) 2003-10-27 2007-01-02 Canji, Inc. Rat secreted embryonic alkaline phosphatase
JP4999467B2 (ja) 2004-02-04 2012-08-15 ファルマアウェア セプシス ビー.ブイ. 粘膜関門に存在するlpsを解毒するためのアルカリホスファターゼの使用
US20110142817A1 (en) 2004-02-04 2011-06-16 Pharmaaware Sepsis B.V. Means and method for treating and/or preventing necrotizing enterocolitis
WO2006096527A2 (en) 2005-03-04 2006-09-14 Diversa Corporation Nucleic acids and proteins and methods for making and using them
US20070059300A1 (en) 2005-09-12 2007-03-15 Zoltan Laboratories Llc Compounds and compositions to control abnormal cell growth
WO2007075199A1 (en) 2005-12-28 2007-07-05 Zoltan Laboratories Llc Use of alkaline phosphatase to maintain healthy tissue mass in mammals
RU2006103770A (ru) * 2006-02-08 2007-08-20 Тихоокеанский Институт Биоорганической Химии Дальневосточного Отделения Российской Академии Наук (Тибох Дво Ран) (Ru) Высокоактивная бактериальная щелочная фосфатаза и фрагмент днк, кодирующий щелочную фосфатазу
US20070280922A1 (en) 2006-06-06 2007-12-06 Zoltan Kiss Consulting Combinations of human proteins to enhance viability of stem cells and progenitor cells
US7718170B2 (en) 2006-08-21 2010-05-18 Essential Skincare, Llc Alkaline phosphatase compositions to reduce skin cancer
EP1952823A1 (en) * 2007-01-30 2008-08-06 AM-Pharma B.V. The use of alkaline phosphatase in the treatment of reduced renal function
WO2008104199A1 (en) 2007-03-01 2008-09-04 Gelato Corporation N.V. Use of ecto-phosphatases for the treatment of (acute) myocardial infarction
EP1985697A1 (en) 2007-04-27 2008-10-29 AM-Pharma B.V. Modified phosphatases
AU2008250945B2 (en) * 2007-05-11 2013-12-12 Alexion Pharmaceuticals, Inc. Bone targeted alkaline phosphatase, kits and methods of use thereof
EP2030980A1 (en) 2007-08-28 2009-03-04 AM-Pharma B.V. Mutants of lactoferrin
WO2009106368A1 (en) 2008-02-29 2009-09-03 Gelato Corporation N.V. Method for increasing the activity of the immune system of a mammal at risk of inflammatory diseases
JP2011521916A (ja) 2008-05-19 2011-07-28 バーナム インスティテュート フォー メディカル リサーチ 腸アルカリホスファターゼモジュレーターおよびそれの使用
CA2732438A1 (en) 2008-08-29 2010-03-04 The General Hospital Corporation Methods of modulating gastrointestinal tract flora levels with alkaline phosphatase
BR112012027765A2 (pt) * 2010-04-30 2019-09-24 Enobia Pharma Inc métodos, composições e kits para tratamento de distúrbios de mineralização da matriz.
HUE052383T2 (hu) * 2011-06-08 2021-04-28 Am Pharma Bv Az alkalikus foszfatáz alkalmazása a vesemûködés megõrzésére
PH12016501441B1 (en) 2014-01-24 2023-02-22 Am Pharma Bv Chimeric alkaline phosphatase-like proteins
PT3461891T (pt) 2014-01-24 2020-07-30 Am Pharma Bv Processamento a jusante de uma fosfatase alcalina

Also Published As

Publication number Publication date
CA2937328A1 (en) 2015-07-30
AU2015209783B2 (en) 2020-10-01
JP6940949B2 (ja) 2021-09-29
NZ722253A (en) 2021-11-26
US20210163905A1 (en) 2021-06-03
US9926544B2 (en) 2018-03-27
PH12016501441A1 (en) 2016-08-22
KR102166110B1 (ko) 2020-10-16
US20190024062A1 (en) 2019-01-24
RU2016131879A3 (pl) 2018-08-16
RU2683635C2 (ru) 2019-03-29
EP3097189B1 (en) 2018-07-11
IL246898A0 (en) 2016-09-29
DK3097189T3 (en) 2018-09-03
HUE039784T2 (hu) 2019-02-28
IL246898B (en) 2019-09-26
JP2020058375A (ja) 2020-04-16
WO2015112017A1 (en) 2015-07-30
MX369041B (es) 2019-10-25
PH12016501441B1 (en) 2023-02-22
SI3097189T1 (sl) 2018-10-30
MX2016009625A (es) 2017-05-01
RU2016131879A (ru) 2018-03-01
US11746340B2 (en) 2023-09-05
BR112016017041A2 (pt) 2017-10-03
PE20161442A1 (es) 2017-01-12
EP3097189A1 (en) 2016-11-30
KR20160117487A (ko) 2016-10-10
SG11201606060WA (en) 2016-08-30
CN106164262B (zh) 2020-08-07
US20170009216A1 (en) 2017-01-12
JP2017505128A (ja) 2017-02-16
SA516371532B1 (ar) 2019-02-11
BR112016017041B1 (pt) 2023-09-26
ES2684639T3 (es) 2018-10-03
EP3425048A1 (en) 2019-01-09
JP7408734B2 (ja) 2024-01-05
CN106164262A (zh) 2016-11-23
US10822597B2 (en) 2020-11-03
US20240174994A1 (en) 2024-05-30
JP2022160503A (ja) 2022-10-19
CN111778228A (zh) 2020-10-16
AU2015209783A1 (en) 2016-08-04
CA2937328C (en) 2022-09-27
ZA201605028B (en) 2020-02-26

Similar Documents

Publication Publication Date Title
IL286393A (en) Smart connection interface
PL3097189T3 (pl) Chimeryczne białka podobne do alkalicznej fosfatazy
DK3197453T3 (da) Kimært protein
DK3180363T3 (da) Sirp-alpha-immunoglobulin fusionsproteiner
DK3137587T3 (da) Detergentsammensætning
PT3101032T (pt) Onjugado de anticorpo anti-her2-fármaco
DE112015001474A5 (de) Doppelkupplung
DK3164414T3 (da) Antistoffer for IL-15
DK3107562T3 (da) P97-ids-fusionsproteiner
PL3234071T3 (pl) Piec
IL291164A (en) Anti-nme antibody
DK3237432T3 (da) Proteinfremstilling
DE112015001577A5 (de) Doppelkupplung
DK3099791T3 (da) Protein
DE112015003929A5 (de) Doppelkupplung
DK3154689T3 (da) Komplekser
HUE047455T2 (hu) HPA-1A elleni antitestek
HUE054148T2 (hu) Anti-ORAI1 antitest
HRP20182029T1 (hr) Uti-fuzijski proteini
LT3628731T (lt) Naujas antipresepsino antikūnas
DK3099793T3 (da) Protein
DK3154945T3 (da) Komplekser
DK3126521T3 (da) HNF4G-RSPO2-fusionsgen
HUE047581T2 (hu) Készítmény
DE102014210430A8 (de) Reinigungsgerät